entri
human
immunodefici
viru
type
target
cell
mediat
envelop
protein
membran
fusion
interact
two
extravirion
heptad
repeat
hr
play
pivot
role
fusion
inhibitor
enfuvirtid
block
entri
identifi
agent
block
fusion
two
screen
method
base
detect
quantif
enzymelink
immunosorb
assay
elisa
principl
establish
one
method
use
alkalin
phosphatas
alp
conjug
antibodi
abelisa
use
alpfus
hr
felisa
detect
quantifi
interact
two
hr
felisa
simpl
rapid
sinc
alpconjug
antibodi
reaction
requir
elisa
detect
fusion
inhibitor
test
except
interact
two
hr
observ
elisa
even
presenc
dimethyl
sulfoxid
abelisa
perform
best
ph
rang
felisa
perform
best
ph
rang
result
indic
establish
elisa
suitabl
identif
fusion
inhibitor
combin
chemotherapi
wide
use
reduc
mortal
caus
infect
prolong
therapi
howev
patient
efficaci
attenu
emerg
drugresist
variant
calmi
et
al
moreov
combin
chemotherapi
occasion
induc
variou
advers
effect
may
also
increas
cost
therapi
therefor
develop
novel
drug
suppress
replic
resist
variant
less
toxic
less
cost
urgent
need
least
two
approach
control
replic
resist
variant
andor
reduc
unfavor
advers
effect
induc
therapi
one
approach
develop
drug
inhibit
new
target
viral
integras
hazuda
et
al
cellular
receptor
tagat
et
al
actual
integras
inhibitor
raltegravir
grinsztejn
et
al
antagonist
maraviroc
et
al
approv
clinic
applic
develop
modif
current
drug
inhibit
correspond
author
tel
fax
email
address
ekodama
viruskyotouacjp
e
kodama
wellestablish
target
make
effect
resist
variant
reduc
advers
sideeffect
studi
focu
recent
establish
promis
target
viruscel
membran
fusion
mechan
viruscel
membran
fusion
alreadi
disclos
eckert
kim
briefli
one
envelop
glycoprotein
bind
host
cell
receptor
anoth
membranespan
protein
trimer
anchor
host
cell
membran
anchor
heptad
repeat
two
extravirion
region
form
antiparallel
bundl
lead
fusion
host
cell
membran
basi
molecular
mechan
compound
prevent
bundl
format
potenti
fusion
inhibitor
enfuvirtid
first
peptid
approv
use
variant
refractori
effect
revers
transcriptas
proteas
inhibitor
lalezari
et
al
lazzarin
et
al
previous
other
develop
novel
potent
fusion
inhibitor
form
peptid
bewley
et
al
otaka
et
al
root
et
al
fig
small
molecul
cai
gochin
frey
et
al
howev
fusion
inhibitor
except
approv
clinic
use
screen
potenti
fusion
inhibitor
establish
two
simpl
rapid
reproduc
deriv
otaka
et
al
shown
residu
number
peptid
correspond
posit
envelop
protein
clone
repres
region
use
studi
defin
amino
acid
respect
design
protein
describ
section
x
indic
artifici
amino
acid
norleucin
instead
methionin
avoid
oxid
methionin
residu
vitro
screen
system
use
enzymelink
immunosorb
assay
elisa
peptidebas
fusion
inhibitor
synthes
describ
previous
otaka
et
al
sequenc
shown
fig
antagonist
baba
et
al
provid
takeda
pharmaceut
compani
ltd
osaka
japan
aid
research
refer
reagent
program
antagonist
de
clercq
et
al
provid
shigeta
fukushima
medic
univers
fukushima
japan
adsorpt
inhibitor
dextran
sulfat
mw
baba
et
al
purchas
sigma
st
loui
mo
dna
fragment
alkalin
phosphatas
alp
code
region
without
secretori
signal
sequenc
correspond
amino
acid
dodt
et
al
kikuchi
et
al
amplifi
pcr
e
coli
genom
strain
genbank
access
number
amplifi
alp
region
ligat
vector
novagen
madison
wi
creat
thioredoxin
trx
alp
fusion
construct
dna
fragment
code
region
amino
acid
posit
amplifi
pcr
molecular
clone
genbank
access
number
amplifi
region
ligat
vector
new
england
biolab
ipswich
express
maltosebind
protein
mbp
tag
design
region
amino
acid
posit
also
amplifi
ligat
vector
ge
healthcar
buckinghamshir
uk
construct
express
fusion
protein
glutathion
stransferas
gst
trxalp
design
respect
vector
verifi
dna
sequenc
transform
e
coli
ril
strain
stratagen
la
jolla
ca
bacteri
express
express
protein
purifi
amylos
resin
new
england
biolab
glutathion
sepharos
ge
healthcar
ninta
agaros
qiagen
valencia
ca
respect
accord
manufactur
recommend
protocol
puriti
determin
sdspage
concentr
bradford
protein
assay
biorad
hercul
ca
fifti
nanomolar
dissolv
mm
sodium
carbon
buffer
ph
coat
elisa
plate
costar
cambridg
incub
c
h
wash
three
time
pb
contain
tween
tpb
ph
plate
block
use
bovin
serum
albumin
bsa
concentr
mgml
tpb
c
h
wash
describ
plate
allow
bind
nm
incub
c
h
presenc
absenc
variou
concentr
compound
test
wash
bind
detect
use
alkalin
phosphatas
alp
conjug
antigst
antibodi
sigma
dilut
c
h
wash
prior
addit
phosphatas
substrat
phosphat
bcip
bluepho
microwel
phosphatas
substrat
kpl
gaithersburg
md
incub
room
temperatur
min
absorb
nm
measur
plate
reader
model
biorad
procedur
perform
describ
except
nm
use
place
bind
directli
detect
bluepho
microwel
phosphatas
substrat
without
interact
alpconjug
antigst
antibodi
activ
determin
multinuclear
activ
galactosidas
indic
magi
assay
describ
previous
kimpton
emerman
kodama
et
al
briefli
magi
cell
cellswel
seed
flat
bottom
microtitr
plate
follow
day
cell
inocul
cultur
presenc
variou
concentr
inhibitor
fresh
medium
h
incub
blue
cell
stain
xgal
well
count
establish
novel
assay
system
repres
specif
interact
region
protein
simpl
elisa
first
establish
alpconjug
antibodi
abelisa
shown
fig
coat
onto
elisa
plate
block
bsa
solut
ad
coat
well
use
alpconjug
antigst
antibodi
interact
colorimetr
measur
plate
reader
agent
block
interact
reduc
optic
densiti
nm
od
period
effici
coat
plate
measur
detect
alpconjug
antimbp
antibodi
h
h
littl
increas
effici
coat
observ
data
shown
coat
block
perform
prior
assay
total
time
procedur
exclud
wash
h
prior
evalu
fusion
inhibitor
examin
interact
coat
first
coat
mbp
without
concentr
nm
incub
variou
concentr
detect
bound
antigst
antibodi
interact
dosedepend
manner
least
provid
suffici
od
valu
fig
thu
nm
use
experi
next
modifi
abelisa
use
alpfus
instead
reaction
coat
shown
fig
felisa
alpfus
enabl
us
directli
detect
interact
without
antibodi
reaction
step
thu
provid
even
rapid
simpl
procedur
abelisa
use
alpconjug
antibodi
detect
total
time
requir
felisa
exclud
coat
block
approxim
h
result
demonstr
elisa
system
detect
interact
interact
enabl
screen
potenti
fusion
inhibitor
without
need
infecti
materi
simpl
rapid
efficaci
fusion
inhibitori
peptid
compound
determin
abelisa
fig
felisa
fig
elisa
detect
activ
three
fusion
inhibitori
peptid
entri
inhibitor
tabl
inhibitori
effect
peptid
fusion
inhibitor
reproduc
display
sigmoid
dosedepend
curv
fig
e
result
suggest
establish
elisa
specif
interact
fusion
process
higher
sensit
peptid
test
obtain
felisa
compar
abelisa
tabl
howev
compar
magi
assay
sensit
elisa
lower
neither
elisa
techniqu
abl
detect
inhibitori
effect
amount
bind
measur
alpconjug
antigst
antibodi
c
direct
detect
interact
without
antibodi
reaction
use
alpfus
protein
multinuclear
activ
galactosidas
indic
assay
use
hela
indic
cell
kimpton
emerman
antifus
activ
vitro
vivo
even
though
amino
acid
region
predict
site
interact
includ
fusion
protein
fig
f
tabl
examin
effect
suscept
chang
coat
interact
experi
first
coat
expos
final
detect
antimbp
antibodi
deriv
effect
data
shown
screen
compound
frequent
dissolv
dimethyl
sulfoxid
dmso
howev
high
concentr
dmso
reduc
cell
viabil
cellbas
assay
eg
magi
assay
elisa
system
describ
requir
cell
thu
less
influenc
dmso
concentr
compar
magi
assay
verifi
determin
concentr
dmso
affect
interact
elisa
abelisa
felisa
dmso
concentr
influenc
optic
densiti
signific
extent
fig
concentr
optic
densiti
record
less
lower
compar
record
absenc
dmso
indic
sensit
test
would
suffici
screen
compound
dissolv
reagent
contain
dmso
next
investig
effect
ph
detect
elisa
high
concentr
compound
highli
acid
basic
may
decreas
viabil
cell
cellbas
assay
ph
reaction
buffer
modifi
addit
hcl
naoh
control
acid
basic
compound
respect
felisa
bind
greater
ph
less
ph
abelisa
bind
rel
stabl
ph
fig
reduct
bind
less
hand
basic
ph
bind
rel
stabl
ph
elisa
result
indic
system
less
influenc
dmso
concentr
basic
reaction
condit
compar
cellbas
assay
howev
acid
reaction
condit
interact
like
overestim
felisa
fig
effect
dmso
concentr
ph
effect
dmso
ad
reaction
shown
bind
express
percentag
absenc
dmso
alter
ph
reaction
perform
use
hcl
naoh
b
bind
express
percentag
ph
newli
establish
elisa
system
success
detect
hivfus
inhibitori
activ
peptidebas
fusion
inhibitor
fig
deriv
dosedepend
manner
howev
lack
ntermin
amino
acid
contain
addit
amino
acid
ctermin
region
show
activ
either
elisa
system
fig
tabl
believ
inhibit
bundl
format
competit
physiolog
region
hypothesi
strongli
support
introduct
site
mutat
resist
vivo
variant
isol
treat
patient
frequent
display
mutat
region
especi
amino
acid
includ
aquaro
et
al
cabrera
et
al
mink
et
al
poveda
et
al
rimski
et
al
wei
et
al
fig
interestingli
amino
acid
posit
also
crucial
bind
resist
variant
also
show
crossresist
nameki
et
al
moreov
preliminari
data
time
cours
addit
experi
show
profil
inhibit
ident
data
shown
design
contain
presum
interact
site
amino
acid
posit
determin
crystal
structur
analysi
complex
chan
et
al
fig
howev
fail
detect
inhibitori
activ
elisa
system
fig
f
best
knowledg
report
describ
potent
activ
proteinor
peptidebas
assay
cai
gochin
huang
et
al
huang
et
al
jiang
et
al
liu
et
al
ryu
et
al
xu
et
al
regard
two
group
tri
reveal
mechan
action
mainli
physicochem
experi
group
propos
may
act
lipid
membran
jiang
et
al
propos
peptid
two
differ
function
domain
domain
lipidbind
domain
contain
sequenc
lipidbind
domain
lipidbind
domain
suggest
might
function
presenc
lipid
membran
wexlercohen
shai
also
found
ctermin
region
includ
could
replac
fatti
acid
indic
act
lipid
membran
possibl
mbp
hamper
proper
conform
howev
bundl
crystal
structur
human
cell
leukemia
viru
type
mbp
remain
fuse
ntermin
kobe
et
al
thu
unlik
inabl
bind
due
improp
conform
moreov
even
synthet
peptid
bind
liu
et
al
date
sever
peptidebas
detect
system
report
although
fail
demonstr
activ
util
monoclon
antibodi
recogn
discontinu
epitop
present
complex
detect
conform
huang
et
al
huang
et
al
jiang
et
al
liu
et
al
predict
system
may
detect
peptidebas
fusion
inhibitor
may
detect
deriv
sinc
antibodi
deriv
conform
peptid
ryu
et
al
also
report
similar
elisa
system
show
inhibitori
effect
ec
valu
gml
approxim
nm
group
report
develop
assay
system
use
fluoresc
reson
energi
transfer
fret
cai
gochin
xu
et
al
although
fret
requir
coat
wash
step
seem
less
sensit
compar
elisa
system
fact
ec
valu
fret
system
describ
approxim
xu
et
al
abelisa
felisa
nm
respect
tabl
sensit
elisa
system
lower
cellbas
magi
assay
tabl
howev
elisa
system
could
detect
interact
even
high
concentr
dmso
rel
wide
ph
rang
fig
indic
capac
screen
highli
concentr
compound
decreas
concentr
increas
antivir
sensit
although
also
reduc
detect
sensit
alp
activ
detect
sensit
could
increas
use
highli
sensit
chemiluminesc
probe
altern
bcip
substrat
use
ph
greater
elisa
show
decreas
optic
densiti
ph
less
enhanc
alp
activ
observ
felisa
compar
neutral
ph
fig
although
could
elucid
detail
mechan
present
even
abelisa
optic
densiti
also
enhanc
use
acid
buffer
incub
antigst
antibodi
data
shown
thu
low
ph
enhanc
alp
activ
rather
enhanc
interact
result
indic
take
note
artifici
enhanc
acid
compound
screen
felisa
major
differ
class
class
ii
fusion
base
upon
structur
glycoprotein
involv
fusion
process
instanc
hiv
fluv
util
alphahelix
structur
domain
locat
respect
contrast
flavivirus
fuse
class
ii
util
betasheet
structur
domain
e
protein
although
glycoprotein
complet
fusion
trimer
hairpin
alphahelix
betasheet
respect
prefus
state
form
trimer
dimer
class
class
ii
respect
moreov
fusion
peptid
domain
directli
insert
target
cell
membran
locat
nterminu
intern
loop
envprotein
class
class
ii
respect
viruscel
membran
fusion
step
interact
viral
envelop
protein
common
mechan
class
fusion
jahn
et
al
schibli
weissenhorn
expect
establish
similar
elisa
screen
system
virus
use
class
fusion
cell
entri
influenza
viru
eckert
kim
felin
immunodefici
viru
fiv
medina
et
al
sever
acut
respiratori
syndrom
coronaviru
sarscov
bosch
et
al
ebola
viru
watanab
et
al
possibl
highli
virul
agent
sarscov
ebola
viru
system
extrem
use
tool
sinc
requir
infecti
materi
studi
develop
two
novel
vitro
assay
system
fusion
inhibitor
focus
interact
envelop
protein
hydrophob
pocket
tryptophan
rich
domain
act
pocket
knob
respect
play
key
role
viruscel
membran
fusion
process
indic
interact
attract
target
small
molecul
fusion
inhibitor
ferrer
et
al
use
studi
contain
knob
region
develop
system
also
ideal
initi
screen
low
variabl
good
reproduc
even
high
compound
concentr
sinc
allow
noninfecti
rapid
simpl
procedur
assay
use
discoveri
novel
fusion
inhibitor
also
virus
util
class
fusion
mechan
